NovoCure Limited announced that its Optune Lua device has received national reimbursement approval in Japan for the treatment of advanced non‑small cell lung cancer (NSCLC). The approval, granted by the Ministry of Health, Labour and Welfare on March 2 2026, allows the device to be covered under Japan’s National Health Insurance system for patients who have progressed on or after platinum‑based chemotherapy and are receiving PD‑1/PD‑L1 inhibitors.
Japan’s oncology market is one of the largest in the world, with an estimated 100,000 new NSCLC cases each year. The approval opens a significant revenue opportunity for NovoCure, positioning Optune Lua as a new treatment option in a market that is projected to grow from USD 3.33 billion in 2023 to USD 9.38 billion by 2032, a CAGR of 12.46%.
In its most recent quarterly report, NovoCure posted Q4 2025 revenue of USD 174.4 million, an 8% year‑over‑year increase, and a full‑year 2025 revenue of USD 655.4 million, also up 8% YoY. The company guided 2026 revenue to USD 675 million‑USD 705 million, reflecting a modest 3%‑8% growth outlook. Despite the revenue rise, NovoCure reported a Q4 2025 net loss of USD 24.5 million and a full‑year 2025 net loss of USD 136 million. Gross margin contracted to 76% in Q4 2025 from 79% the prior year, driven by the rollout of the Head Flexible Electrode (HFE) array for Optune Gio, costs associated with treating NSCLC patients before reimbursement was established, and increased tariffs. Management expects gross margin to remain in the mid‑70% range for 2026.
Hidehito Kotani, Vice President of Asia Pacific, said, “Lung cancer remains one of the leading causes of cancer deaths in Japan. Healthcare providers and patients have an urgent need for approved treatment options. The Ministry’s reimbursement decision for Optune Lua through National Health Insurance gives advanced NSCLC patients a new therapeutic choice.” CEO Frank Leonard added, “In 2025, a record number of patients received our Tumor Treating Fields therapy, and the U.S. FDA approval of Optune Pax for pancreatic cancer demonstrates our expanding multi‑indication platform.” Executive Chairman Bill Doyle noted that 2025 was “a year of progress and change,” highlighting record net revenue of USD 655 million, up 8% from 2024.
The Japan approval strengthens NovoCure’s strategy to diversify beyond glioblastoma and build a multi‑indication portfolio. While the company continues to invest in new indications and device iterations, the reimbursement decision mitigates some headwinds from margin compression and supports the company’s path toward profitability. The approval also positions NovoCure to capture a growing share of the Japanese NSCLC market, where immunotherapies and targeted therapies dominate, giving the company a competitive foothold in a high‑reimbursement environment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.